

REMARKS

A new Sequence Listing setting forth the sequences of SEQ ID NOS:1-13 is filed concurrently herewith. The sequences of SEQ ID NOS:1-13 appear in the specification at pages 12, 13, 15, and 16. The Examiner is respectfully requested to enter the Sequence Listing.

In addition, the specification has been amended at page 15, line 5 to revise the numbering of the sequence identifier for the primer sequence, now listed as SEQ ID NO:13. Applicants inadvertently numbered two sequences as SEQ ID NO:12 (see page 16, lines 21-22). No new matter is added by this amendment. Entry of the amendment is respectfully requested.

The Examiner indicated in a telephonic communication on May 8, 2006 that the application will be in condition for allowance upon submission of a Sequence Listing that complies with the sequence rules.

CONCLUSION

In light of the above remarks, Applicants submit that the present application is fully in condition for allowance. Early notice to that effect is earnestly solicited.

If the Examiner contemplates other action, or if a telephone conference would expedite allowance of the claims, Applicants invite the Examiner to contact the undersigned.

The Commissioner is hereby authorized to charge any fees and credit any overpayment of fees which may be required under 37 C.F.R. §1.16, §1.17, or §1.21, to Deposit Account No. 18-1648.

Please direct all further written communications regarding this application to:

Rebecca M. Hale
Novartis Vaccines & Diagnostics
Intellectual Property - R440
P. O. Box 8097
Emeryville, CA 94662-8097

Respectfully submitted,

Date: May 10, 2006

By: Jenny Buchbinder
Jenny Buchbinder, Ph.D.
Registration No. 48,588
(650) 354-3383

CHIRON CORPORATION
Intellectual Property - R440
P. O. Box 8097
Emeryville, CA 94662-8097